Silver Book Fact

Using technologies as treatment for heart disease helps generate cost savings, including a total of $1930 annual savings per person, and a $1.5 billion increased tax revenue

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Assuming that Medicare Part D covers about 37% of beneficiaries’ drug costs, it is estimated that providing post-myocardial infarction Medicare beneficiaries with full coverage for combination pharmcotherapy will save more…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • “Sherri Selph was 41 when she was first diagnosed with second-stage congestive heart failure. However, her rapidly diminishing health led to a diagnosis of end-stage heart disease. A heart transplant…  
  • From 1979 to 2005, the total number of inpatient cardiovascular operations and procedures increased 484% to 6,989,000 annually.